newsfilter
← Latest News
GlobeNewswire·

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YDES
  • YD Bio Limited expanded U.S. access to its OkaiDx blood-based testing platform for pancreatic and colorectal cancer detection across 44 states via EG BioMed's CLIA/CAP-certified laboratory.
  • The expanded service includes a nationwide telehealth physician network for virtual consultations and test authorization, along with an at-home blood collection partner for sample logistics.
  • New memorandums of understanding with multiple medical groups integrate OkaiDx testing into primary care and women's health clinical workflows.
  • Updated clinical data from EG BioMed US Inc. showed 93.8% sensitivity for early-stage pancreatic ductal adenocarcinoma, 100% sensitivity for late-stage disease, 97.3% specificity in healthy individuals, and 97.7% overall accuracy.
  • The study involved 100 pancreatic cancer patients and 500 healthy controls, highlighting the potential of cfDNA methylation biomarkers like ZFP30 for earlier detection.
  • The OkaiDx Detect Pancreatic Cancer test remains under validation and has not received clearance or approval from the U.S. Food and Drug Administration.
  • YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection, ophthalmologic innovations, drug development, and stem cell therapies.